Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023

Hummingbird Bioscience Singapore United Kingdom

HMBD-001 is Hummingbird Bioscience's proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials in Australia, targeting multiple solid tumors The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe treatment-related adverse eventsDisease control rate (DCR) was 43% (9/21), with one patient achieving a partial response after two cycles of HMBD-001 monotherapy and a best overall response of 51% tumor shrinkageView original content:https://www.prnewswire.co.uk/news-releases/hummingbird-bioscience-announces-positive-phase-i-clinical-data-for-hmbd-001-monotherapy-trial-at-the-european-society-for-medical-oncology-congress-2023-301964143.html